Zimmer Biomet Holdings (ZBH) delivered mixed results in Q2 FY2026 on revenue of $2.2B versus the $2.1B estimate (+4.8% YoY) and EPS of $2.07. The next Zimmer Biomet Holdings (ZBH) earnings date is Nov 4, 2026. Below is the full Zimmer Biomet Holdings earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
$2.07 (vs $2.01 est · +3.0% surprise · +33.8% YoY)
Share price
$98.66 (-0.1%)
Market cap
$18.8B
Zimmer Biomet Holdings (ZBH) Earnings Analysis — beat / miss history
Quarter
Revenue
EPS
EPS surprise
Next-day move
Verdict
Q3 FY2026
$2.2B vs $2.1B est
$2.07 vs $2.01 est
+3.0%
+1.4%
Mixed
Q2 FY2026
$2.1B vs $2.1B est
$2.09 vs $1.86 est
+12.4%
-13.5%
Mixed
Q1 FY2026
$2.2B vs $2.2B est
$2.42 vs $2.38 est
+1.7%
+6.6%
In line
Q4 FY2025
$2.0B vs $2.0B est
$1.90 vs $1.87 est
+1.6%
-14.2%
In line
Q3 FY2025
$2.1B vs $2.1B est
$2.07 vs $1.98 est
+4.5%
+8.9%
Mixed
Q2 FY2025
$1.9B vs $1.9B est
$1.81 vs $1.77 est
+2.3%
-9.9%
Mixed
Q1 FY2025
$2.0B vs $2.0B est
$2.31 vs $2.30 est
+0.4%
-6.8%
In line
Q4 FY2024
$1.8B vs $1.8B est
$1.74 vs $1.74 est
+0.0%
+2.9%
In line
Top institutional holders
Holder
% outstanding
Shares
Value
QoQ change
Dodge & Cox
12.6%
24.1M
$2.1B
+2.5%
Blackrock, INC.
8.1%
15.6M
$1.3B
+1.8%
Harris Associates L P
6.6%
12.7M
$1.1B
-1.7%
Vanguard Capital Management LLC
6.6%
12.6M
$1.1B
-1.2%
Capital International Investors
6.3%
12.2M
$1.0B
+33.6%
State Street Corp
4.6%
8.9M
$766.3M
+0.6%
Vanguard Portfolio Management LLC
4.4%
8.4M
$726.7M
-2.4%
Geode Capital Management, LLC
2.8%
5.3M
$458.7M
-0.6%
Price T Rowe Associates INC /Md/
2.5%
4.8M
$413.0M
-40.0%
Invesco Ltd.
2.1%
4.0M
$342.6M
+10.4%
Recent insider transactions
Insider
Role
Date
Type
Shares
Value
Campbell Gary Craig
officer: President, Americas
2026-10-01
Buy
1K
—
Campbell Gary Craig
officer: President, Americas
2026-10-01
Sell
1K
—
Campbell Gary Craig
officer: President, Americas
2026-10-01
Buy
2K
—
Campbell Gary Craig
officer: President, Americas
2026-10-01
Sell
480
$42442
Campbell Gary Craig
officer: President, Americas
2026-10-01
Sell
932
$82407
Campbell Gary Craig
officer: President, Americas
2026-10-01
Sell
2K
—
Hatcher Brian Matthew
officer: President, Recon, SET, CMFT
2026-10-01
Other
0
—
Hatcher Brian Matthew
officer: President, Recon, SET, CMFT
2026-10-01
Other
1K
$156374
What you'll find
Next Zimmer Biomet Holdings (ZBH) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Zimmer Biomet Holdings reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Zimmer Biomet Holdings (ZBH)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Zimmer Biomet Holdings's next earnings date?
Zimmer Biomet Holdings's (ZBH) next scheduled earnings date is Nov 4, 2026. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Zimmer Biomet Holdings (ZBH) beat or miss earnings?
In Q2 FY2026, Zimmer Biomet Holdings (ZBH) posted mixed results — revenue of $2.2B versus the $2.1B estimate (+2.0% surprise) and EPS of $2.07 versus $2.01 expected (+3.0% surprise). Magnisto decodes every Zimmer Biomet Holdings (ZBH) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
How often does Zimmer Biomet Holdings beat earnings estimates?
Over its last 8 reported quarters, Zimmer Biomet Holdings (ZBH) beat Wall Street EPS estimates 4 times, most recently a mixed result in Q3 FY2026. Magnisto tracks every Zimmer Biomet Holdings (ZBH) quarter's revenue and EPS versus consensus and grades each one Beat, Miss, In-line or Mixed at a unified ±2% threshold.
How much does Zimmer Biomet Holdings stock move after earnings?
Over its last 8 quarterly reports, Zimmer Biomet Holdings (ZBH) moved an average of ±8.0% the day after earnings — ranging from -14.2% (Q4 FY2025) to +8.9% (Q3 FY2025). The stock rose after 4 of those 8 reports and fell after 4. Heading into its next report on Nov 4, 2026, options-implied volatility is pricing in a move of roughly ±5.3% (derived). Magnisto tracks the realized post-earnings move for every Zimmer Biomet Holdings (ZBH) quarter alongside the beat/miss verdict — past moves don't predict the next one.
Who are the largest shareholders of Zimmer Biomet Holdings?
Institutions hold about 102.7% of Zimmer Biomet Holdings's (ZBH) shares outstanding as of the 2026-06-30 13F quarter. Its largest institutional holders include Dodge & Cox (12.6%), Blackrock, INC. (8.1%), Harris Associates L P (6.6%). Magnisto lists Zimmer Biomet Holdings's (ZBH) top 13F holders with each stake size and its quarter-over-quarter change.
Are insiders buying or selling Zimmer Biomet Holdings (ZBH)?
In the most recent Form 4 filings Magnisto tracks, Zimmer Biomet Holdings (ZBH) insiders recorded 2 purchases and 4 sales — net selling. Insider transactions are one signal among many and are often routine (option exercises or scheduled 10b5-1 sales), so Magnisto shows the raw feed for you to judge.
What is the forecast for Zimmer Biomet Holdings (ZBH) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Zimmer Biomet Holdings (ZBH), anchored to the current $98.66 share price, so you can weigh the bull, base and bear cases for Zimmer Biomet Holdings side by side.
Is Zimmer Biomet Holdings (ZBH) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Zimmer Biomet Holdings fits your own thesis and risk profile. This is research, not investment advice.